Literature DB >> 23586952

Fed-batch cultivation of Escherichia coli expressed designer hepatitis C virus diagnostic intermediate and its evaluation.

Chandrasekhar Gurramkonda1, Sheikh M Talha, Satheesh Kumar Gudi, Venkateswara Rao Gogineni, Krothapalli Raja Surya Sambasiva Rao.   

Abstract

The present study aimed for an enhanced induction strategy combined with high-level production of a capture antigen of hepatitis C virus (HCV) for use in diagnosis of HCV infection. We have expressed the synthetic gene encoding for HCV multiepitope protein in pET-28a(+) vector and investigated its production in Escherichia coli BL21(DE3) cells using high-cell-density fed-batch cultivation. A maximum cell dry mass of 30 g/L was obtained, and the culture was induced with 1, 5, and 10 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) for ∼4 H at 30°C; a maximum protein production of 1.5 g/L was observed in the case of induction with 10 mM IPTG. The enhanced induction strategy resulted in a ∼15-fold increase as compared to 1 mM IPTG. The protein was purified using a simple immobilized metal affinity chromatography procedure, yielding 16.6 mg/g dry cell weight of pure protein with more than 99% purity. Further, the protein was evaluated for its diagnostic potential by using the commercially available HCV Seroconversion Panel, Worldwide HCV Performance Panel, and Viral Coinfection Panel. The protein showed high sensitivity and specificity, which was comparable to the best performing commercially available enzyme immunoassay (EIA) kits.
© 2012 International Union of Biochemistry and Molecular Biology, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23586952     DOI: 10.1002/bab.1044

Source DB:  PubMed          Journal:  Biotechnol Appl Biochem        ISSN: 0885-4513            Impact factor:   2.431


  1 in total

1.  Evaluation of a recombinant multiepitope antigen for diagnosis of hepatitis C virus: A lower cost alternative for antigen production.

Authors:  Ronaldo Luis Thomasini; Hortencia Gisele Amaro Souza; Oscar Bruna-Romero; Antonio Helvecio Totola; Neiva Sellan Lopes Gonçales; Cristiano Xavier Lima; Mauro Martins Teixeira
Journal:  J Clin Lab Anal       Date:  2018-02-17       Impact factor: 2.352

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.